Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
The European Medicines Agency (EMA) has updated its notice to sponsors on validating and qualifying computerised systems used in clinical trials. The...
The Medical Device Coordination Group (MDCG) has endorsed non-binding guidance MDCG 2026-6 on clinical evidence for orphan in vitro diagnostic medical...
The Committee of Advertising Practice (CAP) and Broadcast Committee of Advertising Practice (BCAP) have published joint guidance on restrictions on...
This week’s edition of Life Sciences weekly highlights includes the key Autumn Budget 2026 announcements for the life sciences sector, covering new...
The Department of Health and Social Care (DHSC) has announced new UK-wide restrictions banning sales of nicotine-free vapes and nicotine products,...
CASE HUB ARCHIVED—this archived case hub reflects the position at the date of the decision of 3 February 2022; it is no longer maintained.See further,...
CASE HUB ARCHIVED—this archived case hub reflects the position at the date of the judgment of 1 November 2020; it is no longer maintained.See further,...
CASE HUBARCHIVED—this archived case hub reflects the position at the date of the decision to accept commitments on 22 July 2024; it is no longer...
CASE HUBNOTE—appeal lodged before the General Court in Case T- 19/25ARCHIVED–this archived case hub reflects the position at the date of the final...
CASE HUBARCHIVED–this archived case hub reflects the position at the date of the decision of 10 December 2013; it is no longer maintained.See further,...
This Agreement is made on [insert day and month] 20[insert year]Parties1[Insert name of first shareholder] incorporated in England and Wales under...
This Agreement is made on [date]Parties1[insert name of party] [of [insert details ] OR a company incorporated in [England and Wales] under number...
[insert name and address of sender] (We)Our ref: [insert reference]Your ref: [insert reference][Insert address of recipient] (You)1In this letter, the...
[insert address of sender]Our ref: [insert reference]Your ref: [insert reference][insert address of recipient]Date: [insert date]Dear [insert...
[insert address of sender]Our ref: [insert reference]Your ref: [insert reference][insert address of recipient]Date: [insert date]Dear [insert...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
A medicinal product which contains the same active substances and has the same pharmaceutical form as the original branded reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies, as defined in Article 10(2)(b) of Directive 2001/83/EC.
The approval needed to place a medicinal product on the market. It sets out the medical conditions (known as indications), patient population and dosage for which the product is authorised as well as any conditions imposed on the holder of the marketing authorisation.
Unlicensed medicinal products for human use which have been specially manufactured or imported to the order of a doctor, dentist, nurse independent prescriber, pharmacist independent prescriber or supplementary prescriber for the treatment of individual patients in order to fulfil the special needs of an individual patient.